NORGE-MINING-PLC
17.2.2021 08:02:10 CET | Business Wire | Press release
Norge Mining plc , the UK-based exploration company focused on Norway, announces the publication of a maiden Mineral Resource Estimate for the Øygrei area, which confirms the world-class1 characteristics of the Company’s Bjerkreim Exploration Project in south west Norway.
Highlights
- Maiden Mineral Resource Estimate of 1.55 billion tonnes, containing mean grades of 1.74% phosphorus pentoxide, 4.95% titanium dioxide and 0.07% vanadium pentoxide.
- This is a world-class resource of EU Critical Raw Materials, defined as materials of strategic importance for the European economy but for which the EU currently relies on imported supply, and could potentially support a mine life in excess of 50 years.
- Exploration work at Øygrei is ongoing with the aim of improving the understanding of, and extending, the mineral resource.
- During the past two years, Norge Mining has completed more than 25,000m of drilling throughout the Bjerkreim Exploration Project, building on earlier work by the Norway Geological Survey (NGU). The Company expects to report a maiden Mineral Resource Estimate for the Høyland area in the coming months following analysis of information collected from ongoing drilling in that area.
- The Mineral Resource Estimate at Øygrei was prepared according to the JORC2 reporting standard by SRK Exploration Services Ltd (SRK), part of the SRK Group, which is an independent international mining, exploration and environmental consultant.
- The Øygrei Mineral Resource Estimate is summarised below:
Mineral Resource Classification |
Tonnes (millions) |
P2 O5 Grade (%) |
TiO2 Grade (%) |
V2 O5 Grade (%) |
Indicated |
800 |
1.84 |
4.98 |
0.07 |
Inferred |
750 |
1.63 |
4.91 |
0.07 |
Total |
1,550 |
1.74 |
4.95 |
0.07 |
John Vergopoulos, Chief Executive Officer of Norge Mining, said:
“The publication of this Mineral Resource Estimate marks a major milestone for Norge Mining. It confirms that Øygrei alone, which forms a small part of our Bjerkreim Exploration Project, contains a world-class deposit of vanadium, titanium and phosphate. These three minerals are all on the EU’s list of Critical Raw Materials, giving Norway a major opportunity to play a pivotal strategic role in the future supply of these materials.
“Exploration work is ongoing to upgrade and extend the resource at Øygrei, which is just 10 sq km of our total licence area. We are carrying out extensive exploration work in other areas of the Bjerkreim project and expect to announce further Mineral Resource Estimates in the coming months.”
An executive summary of the Øygrei Mineral Resource Estimate is available at the Company’s website: www.norgemining.com
Background to the Bjerkreim Exploration Project
The Bjerkreim Exploration Project is located in the large Bjerkreim-Sokndal Layered Intrusion, which has been widely studied by the Norway Geological Survey (NGU) and other researchers. Norge Mining is focusing on the Bjerkreim Lobe of this intrusion, which forms a large synclinal trough structure. This trough extends at outcrop for some 20km northwest-southeast and up to 10km northeast-southwest. It is known to extend for several kilometres in depth.
The mineralisation consists of primary magmatic mineral assemblages in which vanadium-bearing magnetite, ilmenite (titanium) and apatite (phosphate) represent the minerals of interest. Vanadium, titanium and phosphate are all on the EU’s list of Critical Raw Materials, defined as materials of strategic importance for the European economy but for which the EU currently relies on imported supply.
Through its Norwegian subsidiary Norge Mineraler AS, Norge Mining has 46 exploration licences in south west Norway, totalling more than 400 sq km. During the past two years, the Company has conducted extensive ongoing exploration work at Bjerkreim, including channel sampling, aerial surveys and shallow and deep drilling. In total, more than 25,000m of drilling has been completed.
Øygrei represents one of the areas in the Bjerkreim Exploration Project and is the first area to have reached the stage where a Mineral Resource Estimate can be reported. Øygrei lies on the northern limb of the trough structure where several mineralised zones converge closely.
SRK Exploration Services Ltd (SRK), part of the SRK Group, an international mining, exploration and environmental consultant, has prepared the Mineral Resource Estimate, which brings together the three zones at Øygrei: Zone B, Zone C and New Zone. The diamond drilling programme at Øygrei began in May 2020 and the data cut-off used to produce the resource estimate was 31 December 2020. The data derived from 4,787 assay samples from 24 drill holes.
Øygrei Mineral Resource Estimate
SRK’s initial Mineral Resource Estimate for the Øygrei area of the Bjerkreim Exploration Project, reported according to the JORC Code reporting standard, is summarised below:
Mineral Resource Classification |
Tonnes (millions) |
P2 O5 Grade (%) |
TiO2 Grade (%) |
V2 O5 Grade (%) |
Indicated |
800 |
1.84 |
4.98 |
0.07 |
Inferred |
750 |
1.63 |
4.91 |
0.07 |
Total |
1,550 |
1.74 |
4.95 |
0.07 |
The table shows that the total indicated and inferred mineral resource at Øygrei is 1.55 billion tonnes, which could potentially support a mine life in excess of 50 years.
The vanadium, phosphate and titanium grades are relatively consistent within the three layers that comprise the mineral resource but vary between the layers. Most notably one of the layers, the New Zone, contains a very low phosphate grade (0.11% P2 O5 ) while the other two layers, termed B Zone and C Zone, have mean grades of 1.83% P2 O5 and 2.15% P2 O5 respectively. These two zones together comprise some 1.3 billion tonnes of the total mineral resource and so there would be potential to prioritise the processing of these zones during the mine life and maintain a higher P2 O5 feed grade for a significant period. This will be assessed further as part of the planned Scoping Study.
In reporting a mineral resource, there is a requirement that there are reasonable prospects for eventual economic extraction. In this case, the requirement has been achieved by limiting the tonnage reported to that falling within an open pit which was optimised assuming selling prices of USD230/t of ilmenite, USD97.75/t of phosphate and USD9.2/lb of V2 O5 .
Exploration Target
Norge Mining’s exploration work at Øygrei is ongoing to upgrade and extend the resource. Given the work to extend the resource, SRK has delineated an exploration target, also as defined by the JORC Code, of between 1 and 2 billion tonnes of mineralisation with similar grades to that already reported (between 1.5 and 2% P2 O5 , 4.5 and 5.5% TiO2 and 0.05 and 0.09% V2 O5 ).
This exploration target is based on the assumed continuity of the mineralised layers at Øygrei to the northwest and at depth and has yet to be confirmed by drilling albeit that there is surface geology to support this and the mineralisation drilled to date remains open in these directions. It should be noted that the exploration target potential tonnage and grade estimates are conceptual in nature, that there has been insufficient exploration to estimate a mineral resource and that it is uncertain if further exploration will result in the estimation of a mineral resource.
Next Steps
Exploration work at Øygrei is ongoing with a substantial, planned programme of 14,000m of additional drilling. Data from this drilling work will be used to upgrade and extend the resource and also to provide information for a scoping study, which is expected to begin shortly, to give an initial financial appraisal of the development of Øygrei. The drilling work and scoping study are expected to be completed this year. Norge Mining is also carrying out ongoing exploration work elsewhere in the Bjerkreim Exploration Project.
1 World-class deposit is used in the context of this announcement to mean a deposit of very large size with the potential to provide major economic and strategic benefits.
2 The reporting standard for this statement is the 2012 edition of the “Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves” as published by the Joint Ore Reserves Committee of the Australasian Institute of Mining and Metallurgy, Australian Institute of Geoscientists and Minerals Council of Australia” (the “JORC Code”). The JORC Code is a reporting code which has been aligned with the Committee for Mineral Reserves International Reporting Standards (“CRIRSCO”) reporting template and is an internationally recognised reporting standard that has been adopted worldwide for market-related reporting and financial investments.
The Competent Person who has overall responsibility for the Mineral Resource is Dr Mike Armitage, C.Eng, C. Geol, FGS, MIMM, PhD. Dr Armitage is a Chartered Geologist which is a Recognised Professional Organisation (“RPO”) included in a list promulgated by the Australian Securities Exchange (“ASX”) from time to time. He is a full time employee of SRK Consulting (UK) Ltd and a director of SRK Exploration Services, a corporate consultant and has over 35 years’ experience in the mining and metals industry and also has sufficient experience which is relevant to the style of mineralisation and type of deposit under consideration and to the activity which he is undertaking to qualify as a Competent Person as defined in the JORC Code. Dr Armitage has been responsible for the reporting of Mineral Resources and Ore Reserves on various properties internationally during the past 30 years.
About Norge Mining plc
Norge Mining plc is a UK-based natural resources company focused on mineral exploration in Norway.
The Company owns 46 exploration licences, totalling more than 400 square kilometres in south-west Norway in an area known to contain vanadium, titanium, phosphate and gold. Norge Mining is currently conducting a programme of exploration work to produce a resource estimate, building on earlier studies by the Norway Geological Survey (NGU).
Norge Mining’s ambition is to become a substantial, sustainable and strategically important exploration and mining business focused on Norway.
The Company was founded in November 2018, is headquartered in the UK and has a 100%-owned Norwegian subsidiary, Norge Mineraler AS.
For further information, please visit www.norgemining.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216006223/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
